Trials / Completed
CompletedNCT00405392
Study To Investigate Patient Preference On Dosing In Ibandronate And Risedronate In Korean Women With Postmenopausal Osteoporosis
An Open-label, Multi-centre, Randomized Study to Investigate Patient Preference on Dosing in the Once-monthly Ibandronate and the Once-weekly Risedronate in Korean Women With Postmenopausal Osteoporosis. A Six-month, Two-sequence, and Two Period Crossover Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 365 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- Female
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a randomized open label, multi-centre study for Korean women with postmenopausal osteoporosis, evaluating the preference for either the once-monthly dosing of ibandronate or the once-weekly dosing of risedronate. Eligible subjects will be randomised either ibandronate monthly regimen or risedronate weekly regimen. Treatment period consists of 3 month with ibandronate 150mg and additional 12 week with risedronate 35 mg or vice versa. After taking the first interventional medicine for 3 months or 12 weeks completely, a subject changes the treatment arm. There is no washout period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ibandronate (SB743830HD) |
Timeline
- Start date
- 2007-03-22
- Primary completion
- 2008-05-27
- Completion
- 2008-05-27
- First posted
- 2006-11-30
- Last updated
- 2018-06-06
- Results posted
- 2018-06-06
Source: ClinicalTrials.gov record NCT00405392. Inclusion in this directory is not an endorsement.